Cognition Therapeutics, Inc(CGTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CGTX Cognition Therapeutics, Inc

Market Closed 12-12 16:00:00 EST

1.69

+0.07

+4.32%

盘后1.72

+0.03+1.74%

19:51 EST

High1.76	Low1.61	Vol1.04M
Open1.63	D1 Closing1.62	Amplitude9.26%
Mkt Cap149.18M	Tradable Cap148.26M	Total Shares88.27M
T/O1.78M	T/O Rate1.18%	Tradable Shares87.73M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CGTX","market":"US","secType":"STK","nameCN":"Cognition Therapeutics, Inc","latestPrice":1.69,"timestamp":1765573200000,"preClose":1.62,"halted":0,"volume":1039185,"hourTrading":{"tag":"盘后","latestPrice":1.7194,"preClose":1.69,"latestTime":"19:51 EST","volume":12215,"amount":20793.1241,"timestamp":1765587091168},"delay":0,"floatShares":87726600,"shares":88274258,"eps":-0.455423,"marketStatus":"Market Closed","change":0.07,"latestTime":"12-12 16:00:00 EST","open":1.63,"high":1.76,"low":1.61,"amount":1784656.3103775,"amplitude":0.092593,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.455423,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"listingDate":1633665600000,"exchange":"NASDAQ","adjPreClose":1.62,"preHourTrading":{"tag":"盘前","latestPrice":1.62,"preClose":1.62,"latestTime":"09:24 EST","volume":10745,"amount":17620.5288665,"timestamp":1765549495172},"postHourTrading":{"tag":"盘后","latestPrice":1.7194,"preClose":1.69,"latestTime":"19:51 EST","volume":12215,"amount":20793.1241,"timestamp":1765587091168},"volumeRatio":1.3621410041663178},"requestUrl":"/m/hq/s/CGTX/tweets","defaultTab":"tweets","newsList":[{"id":"2588850218","title":"Cognition Therapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2588850218","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588850218?lang=en_us&edition=fundamental","pubTime":"2025-12-04 19:25","pubTimestamp":1764847500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CGTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 04, 2025 06:25 ET (11:25 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGTX"],"gpt_icon":0},{"id":"2588004521","title":"Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies","url":"https://stock-news.laohu8.com/highlight/detail?id=2588004521","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588004521?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:30","pubTimestamp":1764765000,"startTime":"0","endTime":"0","summary":"- Type C Meeting with U.S. Food and Drug Administration (FDA) Scheduled for Second Half of January -PURCHASE, N.Y., Dec.  03, 2025  (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/03/3198763/0/en/Cognition-Therapeutics-Reaches-Full-Enrollment-in-Expanded-Access-Program-for-Zervimesine-CT1812-in-Dementia-with-Lewy-Bodies.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","DLB","LU0345774631.USD","LU0205194284.USD","LU0205193047.USD","LU0240877869.USD","LU0240878834.USD","LU0348723411.USD","LU0345774391.USD","BK4007","CGTX"],"gpt_icon":0},{"id":"2588727882","title":"Cognition Therapeutics Announces Phase 3 Trials of Zervimesine for Mild-to-Moderate Alzheimer's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2588727882","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588727882?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:30","pubTimestamp":1764592218,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics Inc. has announced plans for a Phase 3 registrational program evaluating zervimesine  in adults with mild-to-moderate Alzheimer's disease. The study will enroll participants with lower plasma p-tau217 levels, a strategy supported by the U.S. Food and Drug Administration  following an end-of-Phase 2 meeting in July 2025. The Phase 3 program will consist of two six-month studies, with participants randomized to receive either 100 mg of oral zervimesine or placebo daily. Efficacy will be measured using the iADRS scale. Results from the Phase 2 \"SHINE\" study, previously presented, indicated that zervimesine slowed cognitive decline in patients with lower p-tau217 levels. Details of the Phase 3 trial design were presented at the Clinical Trials on Alzheimer's Disease  conference held December 1-4, 2025. Cognition Therapeutics is also seeking alignment with the European Medicines Agency  regarding their global registrational plans.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL1M6WFp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2210150020.SGD","LU2095319765.USD","BK4007","BK4585","IE00BKPKM429.USD","BK4112","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU0314104364.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","NDAQ","CGTX"],"gpt_icon":0},{"id":"2588722045","title":"Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (Ct1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (Ctad) Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2588722045","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588722045?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:30","pubTimestamp":1764592200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA1QRRJK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CGTX"],"gpt_icon":0},{"id":"2585148457","title":"B. Riley Raises Price Target on Cognition Therapeutics to $3 From $2, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2585148457","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585148457?lang=en_us&edition=fundamental","pubTime":"2025-11-21 20:43","pubTimestamp":1763728983,"startTime":"0","endTime":"0","summary":"B. Riley Raises Price Target on Cognition Therapeutics to $3 From $2, Keeps Buy Rating","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CGTX","RILY"],"gpt_icon":0},{"id":"2584945452","title":"Cognition Therapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2584945452","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584945452?lang=en_us&edition=fundamental","pubTime":"2025-11-19 20:04","pubTimestamp":1763553840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CGTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 19, 2025 07:04 ET (12:04 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGTX"],"gpt_icon":0},{"id":"2584614943","title":"Cognition Therapeutics (CGTX) Receives a Buy from H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2584614943","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584614943?lang=en_us&edition=fundamental","pubTime":"2025-11-19 19:36","pubTimestamp":1763552211,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Cognition Therapeutics today and set a price target of $3.00. According to TipRank...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cognition-therapeutics-cgtx-receives-a-buy-from-h-c-wainwright-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cognition-therapeutics-cgtx-receives-a-buy-from-h-c-wainwright-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CGTX"],"gpt_icon":0},{"id":"2584646044","title":"Mesoblast Appoints James O'Brien CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2584646044","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584646044?lang=en_us&edition=fundamental","pubTime":"2025-11-17 17:43","pubTimestamp":1763372632,"startTime":"0","endTime":"0","summary":"Mesoblast (MESO) said Monday it has appointed James O'Brien as its chief financial officer.O'Brien previously worked at different pharmaceutical companies, including Bristol-Myers Squibb (BMY) and Cognition Therapeutics (CGTX), the company said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BJJMRZ35.SGD","LU1571399168.USD","BK4585","LU1989771016.USD","BK4559","BMY","IE00BFTCPJ56.SGD","BK4007","LU0306806265.USD","LU1670711040.USD","LU0306807586.USD","LU0882574055.USD","MESO","IE00B2B36J28.USD","LU0096364046.USD","LU2125154778.USD","IE00BFXG1179.USD","BK4139","LU0321505439.SGD","LU1430594728.SGD","IE00BSNM7G36.USD","LU0321505868.SGD","LU1074936037.SGD","LU1093756168.USD","BK4532","LU1261432733.SGD","LU1670710661.SGD","LU0237698245.USD","LU1868837300.USD","LU1585245621.USD","LU2242652126.USD","LU2125154935.USD","LU2360032135.SGD","IE00BJT1NW94.SGD","LU0225771236.USD","LU2242646821.SGD","LU0225284248.USD","IE0002141913.USD","LU0456855351.SGD","LU0868494617.USD","LU1670711123.USD","LU0061475181.USD","BK4534","LU1868836757.USD","LU1718418525.SGD","LU2133065610.SGD","LU1868837136.USD","CGTX","LU1291159041.SGD","LU1093756325.SGD"],"gpt_icon":0},{"id":"2584692141","title":"BUZZ-Mesoblast's Australian shares climb as O'Brien becomes finance chief of US division","url":"https://stock-news.laohu8.com/highlight/detail?id=2584692141","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584692141?lang=en_us&edition=fundamental","pubTime":"2025-11-17 09:11","pubTimestamp":1763341876,"startTime":"0","endTime":"0","summary":"BUZZ-Mesoblast's Australian shares climb as O'Brien becomes finance chief of US division** ASX-listed shares of inflammatory disease drug-maker Mesoblast MSB.AX rise as much 3.6% to A$2.3, snapping two sessions of consecutive losses  ** Co appoints James O'Brien as its U.S.-based CFO ** Says Jim's recent CFO roles included NASDAQ-listed biopharmaceutical company Cognition Therapeutics Inc CGTX.O, overseeing successful initial public offering, among others ** Stock is fourth-biggest percentage gainer in the benchmark S&P/ASX 200 index .AXJO ** Stock up 2.7% at A$2.28, as at 0104 GMT** Stock down 26.5% this year, including the day's move  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nL6N3WS06D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","CGTX","BK7501","MSB.AU","BK4007"],"gpt_icon":0},{"id":"2583421567","title":"Cognition Therapeutics Completes Enrollment in Phase 2 Trial of Zervimesine for Early Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2583421567","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583421567?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:36","pubTimestamp":1763037392,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics Inc. announced the completion of enrollment in its Phase 2 randomized, placebo-controlled START study, evaluating zervimesine  in individuals with mild cognitive impairment  or early Alzheimer's disease. The study reached its target enrollment of 540 participants, with additional patients in the final screening stages. The START study, conducted in collaboration with the Alzheimer's Clinical Trials Consortium, is designed to assess the safety and activity of zervimesine. Approximately 15% of participants are also receiving background therapy with either Leqembi  or Kisunla . Topline results are expected after all participants have completed 18 months of treatment. Phase 2 results in mild-to-moderate Alzheimer's disease and dementia with Lewy bodies were presented earlier in 2025 at international conferences and to study investigators.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to pro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL45wDB8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0314104364.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","NDAQ","LU2095319765.USD","LU2210149790.SGD","BK4007","BK4588","IE00BKPKM429.USD","LU2210150020.SGD","BK4112","IE00B3QW5Z07.USD","CGTX"],"gpt_icon":0},{"id":"2581881319","title":"Cognition Therapeutics Inc  expected to post a loss of 9 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581881319","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581881319?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:40","pubTimestamp":1762526418,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics Inc  expected to post a loss of9cents a share - Earnings Preview Cognition Therapeutics Inc CGTX.OQ CGTX.O is expected to  show no change in quarterly revenue when it reports  r","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ1YY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CGTX"],"gpt_icon":0},{"id":"2581098355","title":"Cognition Therapeutics Q3 net loss narrows as trials ending lower R&D costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2581098355","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581098355?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:43","pubTimestamp":1762432982,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics Q3 net loss narrows as trials ending lower R&D costsOverviewCognition Therapeutics reports Q3 net loss of $4.9 mln, down from $9.9 mln last yearCompany completed $30 mln registe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI0OG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGTX","BK4007"],"gpt_icon":0},{"id":"2581060415","title":"Cognition Therapeutics Q3 EPS $(0.06) Beats $(0.09) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581060415","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581060415?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:37","pubTimestamp":1762432667,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics (NASDAQ:CGTX) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.09) by 33.33 percent. This is a 76 percent increase over losses of $(0.25) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48683108/cognition-therapeutics-q3-eps-0-06-beats-0-09-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGTX"],"gpt_icon":0},{"id":"2581060567","title":"Cognition Therapeutics reports Q3 cash position of $39.8 million and R&D expenses of $3.8 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581060567","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581060567?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:30","pubTimestamp":1762432237,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics Inc. reported cash, cash equivalents, and restricted cash of approximately $39.8 million as of September 30, 2025, with $36.3 million in remaining obligated grant funds from the National Institute of Aging. The company estimates this funding is sufficient to support operations and capital expenditures into the second quarter of 2027. Research and development expenses for the third quarter of 2025 were $3.8 million, down from $11.4 million in the same period in 2024, primarily due to the completion of the SHINE and SHIMMER clinical trials. During the period, Cognition completed a $30 million registered direct offering and reported ongoing progress in clinical programs, including surpassing 75% enrollment in the Phase 2 START study for early Alzheimer's disease and an expanded access program for dementia with Lewy bodies. The company also achieved alignment with the FDA on a registration path for zervimesine in Alzheimer's disease.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDLcfxPsp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2210149790.SGD","IE00B64PRP62.GBP","CGTX","LU0314104364.USD","BK4112","IE00B3QW5Z07.USD","LU2095319765.USD","BK4585","LU2210150020.SGD","IE00BGHQF748.EUR","BK4007","NDAQ","BK4588"],"gpt_icon":0},{"id":"2581098387","title":"Cognition Therapeutics Inc - Net Loss $0.06 per Share for Q3 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2581098387","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581098387?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:30","pubTimestamp":1762432203,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUA71R2DN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CGTX"],"gpt_icon":0},{"id":"2581098371","title":"Cognition Therapeutics Inc - Estimates Sufficient Cash to Fund Operations & Capital Expenditures Into Q2 of 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2581098371","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581098371?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:30","pubTimestamp":1762432203,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUA71R2DN:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CGTX"],"gpt_icon":0},{"id":"2581206062","title":"Cognition Therapeutics Q3 Operating Expenses USD 6.375 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581206062","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581206062?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:30","pubTimestamp":1762432203,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nPLX2B3F2D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CGTX","BK4007"],"gpt_icon":0},{"id":"2581060412","title":"Press Release: Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2581060412","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581060412?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:30","pubTimestamp":1762432200,"startTime":"0","endTime":"0","summary":"- $30 Million Registered Direct Offering Support Next Stage of Development for Zervimesine  -. - Aligned with U.S. FDA on Registrational Path for Zervimesine -. - Expanded Access Program for Dementia with Lewy Bodies Ongoing -. PURCHASE, N.Y., Nov. 06, 2025  -- Cognition Therapeutics, Inc.  , a clinical-stage company developing drugs that treat neurodegenerative disorders, today reported financial results for the third quarter ended September 30, 2025, and provided a business update.\"The $30 million registered direct offering enables us to begin preparations for the next stage of development for zervimesine , \" stated Lisa Ricciardi, Cognition's president and CEO. \"The alignment we achieved with the FDA on a registrational path in Alzheimer's disease was an important accomplishment. We were encouraged by the agency's receptivity to study designs and recruitment strategies that support faster, more cost-effective studies. Looking ahead, we believe the clinical pharmacology and bioavaila","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0205193047.USD","BK4097","LU0240877869.USD","DLB","LU0345774391.USD","LU0240878834.USD","CGTX","LU0205194284.USD","LU0348723411.USD","PRGS","BK4007","LU0345774631.USD","LU2065732104.USD"],"gpt_icon":0},{"id":"2567053116","title":"Cognition Therapeutics Advances Zervimesine to Phase 3 Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2567053116","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567053116?lang=en_us&edition=fundamental","pubTime":"2025-09-15 19:30","pubTimestamp":1757935827,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics ( ($CGTX) ) has shared an update. Cognition Therapeutics is advancing its lead product candidate, zervimesine, towards Phase...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cognition-therapeutics-advances-zervimesine-to-phase-3-trials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cognition-therapeutics-advances-zervimesine-to-phase-3-trials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4007","LENZ","BK4139","CGTX"],"gpt_icon":0},{"id":"2564360771","title":"Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Reaches 75% Enrollment Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2564360771","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564360771?lang=en_us&edition=fundamental","pubTime":"2025-09-03 19:30","pubTimestamp":1756899000,"startTime":"0","endTime":"0","summary":"PURCHASE, N.Y., Sept.  03, 2025  (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative dis","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/03/3143480/0/en/Cognition-Therapeutics-Study-of-Zervimesine-CT1812-in-Early-Alzheimer-s-Disease-Reaches-75-Enrollment-Target.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","LU0240878834.USD","BK4139","LU0205194284.USD","LU0205193047.USD","BK4539","LU0345774391.USD","BK4007","CGTX","MCI","BK4097","LU0345774631.USD","LU0240877869.USD","DLB","LU0348723411.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cogrx.com","stockEarnings":[{"period":"1week","weight":-0.0231},{"period":"1month","weight":-0.0174},{"period":"3month","weight":-0.2212},{"period":"6month","weight":4.6654},{"period":"1year","weight":2.3228},{"period":"ytd","weight":1.4098}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.026933},{"month":2,"riseRate":0,"avgChangeRate":-0.237253},{"month":3,"riseRate":0.25,"avgChangeRate":-0.015618},{"month":4,"riseRate":0.75,"avgChangeRate":-0.007447},{"month":5,"riseRate":0.5,"avgChangeRate":-0.080419},{"month":6,"riseRate":0.25,"avgChangeRate":-0.038614},{"month":7,"riseRate":0.25,"avgChangeRate":0.074037},{"month":8,"riseRate":0.5,"avgChangeRate":0.719491},{"month":9,"riseRate":0,"avgChangeRate":-0.232471},{"month":10,"riseRate":0.5,"avgChangeRate":0.012004},{"month":11,"riseRate":0.2,"avgChangeRate":0.100902},{"month":12,"riseRate":0.4,"avgChangeRate":0.141772}],"exchange":"NASDAQ","name":"Cognition Therapeutics, Inc","nameEN":"Cognition Therapeutics, Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cognition Therapeutics, Inc(CGTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cognition Therapeutics, Inc(CGTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cognition Therapeutics, Inc,CGTX,Cognition Therapeutics, Inc股票,Cognition Therapeutics, Inc股票老虎,Cognition Therapeutics, Inc股票老虎国际,Cognition Therapeutics, Inc行情,Cognition Therapeutics, Inc股票行情,Cognition Therapeutics, Inc股价,Cognition Therapeutics, Inc股市,Cognition Therapeutics, Inc股票价格,Cognition Therapeutics, Inc股票交易,Cognition Therapeutics, Inc股票购买,Cognition Therapeutics, Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cognition Therapeutics, Inc(CGTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cognition Therapeutics, Inc(CGTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction